Ascletis Pharma Inc.

Investors

Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2026
2026-05-07
Voluntary Announcement - Ascletis to Present Data on Multiple Programs at the 33rd European Congress on Obesity (ECO 2026)
2026-05-06
Voluntary Announcement - Ascletis to Present Data on Multiple Programs at the American Diabetes Association’s 2026 Scientific Sessions
2026-04-30
Annual Report 2025
2026-04-29
Voluntary Announcement - Ascletis Completes Enrollment in U.S. Phase II Study of ASC30, an Oral Small Molecule GLP-1R Agonist, for the Treatment of Diabetes
2026-04-27
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2026
2026-04-08
Voluntary Announcement - Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development
2026-04-07
Annual Results Announcement for the Year Ended December 31, 2025 and Change in the Use of Proceeds
2026-03-31
Notice of Board Meeting
2026-03-18
Voluntary Announcement - Oral Small Molecule Amylin Receptor Agonist ASC39 Demonstrated Eloralintide-Like Amylin Selectivity and Efficacy in Preclinical Models
2026-03-17

1

© 2018 Ascletis Pharma Inc. All Rights Reserved
浙公网安备 33010802003344号浙ICP备11050387号-1